

AUSTRALIA-TAIWAN BIOTECH COLLABORATION FORUM

Date: Friday 29 July, 2022

Time: 9:00 am – 12:00 pm Taipei [11:00 am – 2:00 pm AEST]

Venue: Room 703, Hall 2, Taipei Nangang Exhibition Center

*活動將全程以英文進行·現場不提供翻譯

Time (Taipei)	Agenda	*Australian speakers join virtually for Q&A
08:30-09:00	Registration and Morning Coffee	
09:00-09:10	Welcome Remarks Ms Jenny Bloomfield, Australian Representative in Taiwan	
	Opening Remarks Dr Chung-hsiu Wu Director, Biotechnology and Pharmaceutical Industries Promotion Office, MOEA Chairman, Taiwan Bio Industry Organisation	
09:10-09:20	Australia: A powerhouse for science and innovation in Biotechnology Rhett Miller Head of Greater China International Health Team Trade and Investment Commissioner, Austrade	
Part 1- Presentation: Australia Clinical Trials Capabilities		
09:20-09:55	Topic	Speaker
	George Clinical – Your CRO Partner for Australia and across the Globe	James Cheong Chief Executive Officer George Clinical
	US Team capability, Phase I capability and Experiences (ANZ), NVT/PPC integration	John Moller Chief Executive Officer Novotech
	Southern Star Research: Early Phase Clinical Study Specialists	Chris Stellatos, Director Southern Star Research
	Neuroscience Trials Australia (NTA): The CRO for all your neuroscience trials in Australia and beyond	Kathy Skoff Senior Business Development Manager Neuroscience Trials Australia
	Nucleus Network : Your Premier Early Phase Clinical Trial Solution Provider Across Australia and USA	Jeffery Wong Director of Business Development Nucleus Network
	Local knowledge, global network: Bioanalytical solutions for Australia and beyond	Angela Luttick EVP, Commercial 360biolabs
	Conducting Clinical Trials in Australia: Corporate Structuring & R&D Incentives	Blair Lucas, Partner Acclime Australia

Time (Taipei)	Agenda	
09:55-10:10	Q&A	
Part 2- Presentations: Australian Innovative Biotech Company Presentation		
10:10-10:35	Topic	Speaker
	MiCheck® Prostate for Detection of Aggressive Prostate Cancer	Dr Brad Walsh Chief Executive Officer Minomic International
	Discovery, development, and market authorisation of microbiome-based therapies	Thomas Mitchell Chief Executive Officer BiomeBank
	Data driven development of microbiome-based therapeutics	Trent Muno SVP Therapeutics Microba Life Sciences
	Your Australian Future: Global Talent Visa Program	Pip Butler Director Global Talent, Hong Kong and North Asia Global Australia Taskforce
10:35-10:50	Q&A	
10:50-11:05	Tea Break	
Part 3: Taiwan Precision Medicine Company Presentation		
11:05 – 11:35	Topic	Speaker
	Code to cure, an enterprise cloud-native BioMed-IT platform to empower biotech and precision medicine industries to innovate at scale and speed	Allen Chang Chief Executive Officer ATGENOMIX
	One-stop services for cell-based products and bioassays	Shing-Mou Lee Chief Executive Officer & Lab Head TACT, Executive Director EMO Biomedicine
	Universal antibody lock makes antibody drugs safer and effective	Yun-Chi Lu Chief Executive Officer PrecisemAb Biotech
	A novel nanobody-based trispecific T cell engager (Nb-TriTE) for cancer immunotherapy	Shao-Chih Chiu Chief R&D Officer Shine-On BioMedical
	Biologic drug industry pain points and how we can help to fill the gap	Alan Chang, Ph.D., Chief Executive Officer Taron Solutions
	Research results of lung cancer urine detection technology	I-Shu Lee, Ph.D. Chief Executive Officer VITAE Biomedical
11:35-11:50	Q&A	
12:00	Event Closing	

*Australian speakers join virtually for Q&A

